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Background: Stroke is a leading cause of death and disability internationally. One of the three effective
interventions in the acute phase of stroke care is thrombolytic therapy with tissue plasminogen activator (tPA), if
given within 4.5 hours of onset to appropriate cases of ischaemic stroke.
Objectives: To test the effectiveness of a multi-component multidisciplinary collaborative approach compared to
usual care as a strategy for increasing thrombolysis rates for all stroke patients at intervention hospitals, while
maintaining accepted benchmarks for low rates of intracranial haemorrhage and high rates of functional outcomes
for both groups at three months.
Methods and design: A cluster randomised controlled trial of 20 hospitals across 3 Australian states with 2 groups:
multi- component multidisciplinary collaborative intervention as the experimental group and usual care as the
control group. The intervention is based on behavioural theory and analysis of the steps, roles and barriers relating
to rapid assessment for thrombolysis eligibility; it involves a comprehensive range of strategies addressing
individual-level and system-level change at each site. The primary outcome is the difference in tPA rates between
the two groups post-intervention. The secondary outcome is the proportion of tPA treated patients in both groups
with good functional outcomes (modified Rankin Score (mRS <2) and the proportion with intracranial haemorrhage
(mRS ≥2), compared to international benchmarks.
Discussion: TIPS will trial a comprehensive, multi-component and multidisciplinary collaborative approach to
improving thrombolysis rates at multiple sites. The trial has the potential to identify methods for optimal care which
can be implemented for stroke patients during the acute phase. Study findings will include barriers and solutions to
effective thrombolysis implementation and trial outcomes will be published whether significant or not.
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Effective treatments for stroke can provide major
reductions in health burden
Stroke is a major cause of death and disability inter-
nationally, with over 5 million deaths from stroke world-
wide [1]. Stroke accounted for approximately 1 in every
19 deaths in the United States in 2009 [2], with US pro-
jections indicating that an additional 4 million people
will have had a stroke by 2030 [3], a 22% increase in
prevalence from 2013 [4]. The mean cost per person for
stroke care in the United States in 2009 was estimated at
$6,018 [5]. In 2009, The Australian Bureau of Statistics
reports an estimated 381,400 Australians (1.8% of the
total population) had suffered a stroke [6], with 35%
reporting at least one impairment as a result of that
stroke [6] and 62% of these reporting their stroke as
their main disabling condition [6]. Stroke was the under-
lying cause of death for 11,220 Australians in 2010 [6]
and is the second leading cause of death and a leading
cause of long-term disability [7]. In 2012, the total finan-
cial cost of stroke was around $5 billion [8] with an esti-
mated burden of disease cost of $49.3 billion [8]. In
2012, there were nearly 50,000 strokes in Australia, with
approximately 12,000 people dying as a result of their
stroke [8]. In 2009 to 2010, 35,345 hospitalisations were
recorded in Australia with a principal diagnosis of stroke
[9] and an average length of stay of 9 days [9]. The ma-
jority of strokes (89%) are admitted to hospital [10], and
approximately 50% of sufferers are left either deceased
or dependent [11].
Improved outcomes for acute stroke can be achieved
by: use of aspirin within 48 hours to provide a modest
absolute risk reduction of 1% [12]; Stroke Care Units
(SCU) [13]; and thrombolytic therapy using intravenous
tissue plasminogen activator (tPA) administered to ap-
propriate patients according to guidelines and within 4.5
hours of symptom onset [14,15]. A systematic review of
randomised trials of intravenous tPA within 6 hours of
acute ischaemic stroke onset found intravenous tPA sig-
nificantly increased the odds of being alive and inde-
pendent (modified Rankin Scale of 0 to 2) at 3-month
follow-up for those treated within 3 hours of onset [16].
Sustained improvements in functional outcome and
health-related quality of life have been identified at up to
18-month follow-up [17]. Treatment benefits for tPA are
highest if administered within 3 hours of stroke onset
[16,18,19] but can extend beyond the 3-hour window
[20], with tPA considered safe for eligible patients up to
4.5 hours after stroke onset [21]. The ‘number needed to
treat’ with tPA to prevent death and dependency is be-
tween 6 and 14, but may be higher depending on the
favourable outcome definition and method of calculation
[15,22,23]. Although there has been some debate about
the strength of the evidence provided by thrombolysis[24,25], the treatment is endorsed via national and inter-
national guidelines [26-29].
Thrombolysis is a cost-effective stroke treatment when
used appropriately
Cost-effectiveness analyses have indicated that high-cost
treatments for acute stroke can provide major public
health benefits even when minor reductions in disability
are achieved [30]. A number of studies have identified
thrombolysis as being a cost-effective treatment when
used appropriately [31-34]. A UK study estimated that
over a lifetime, tPA was associated with cost-savings of
£96,565 per quality-adjusted life year [33]. The Model of
Resource Utilization, Costs, and Outcomes for Stroke
(MORUCOS) study found that tPA saved 155 disability-
adjusted life years in a group of 256 eligible patients and
concluded that tPA is more effective and cost-saving
than treatment with aspirin [32].
Rates of thrombolysis remain low internationally
Despite evidence for the cost-effectiveness and safety of
thrombolysis along with international recommendations
being in place for a number of years [21,35,36], there
has been little overall growth in thrombolysis rates.
Thrombolysis rates have remained relatively low in a
number of countries over the past decade: In the US,
tPA administration rates increased from 0.87% in 2001
to 2.40% in 2006 [37]. In the UK in 2008, while an esti-
mated 26% of acute stroke patients were eligible for
thrombolysis, only 1.4% were administered the treatment
[38]. Only 4.3% of ischemic stroke patients in the California
Acute Stroke Pilot Registry received thrombolysis [3]. In
Australia, despite making major progress in terms of wide
establishment of stroke care units, tPA rates are approxi-
mately 7% [30].
Achieving large-scale increases in rates of thrombolysis is
challenging
Changing practice is an acknowledged challenge in a
number of settings [39]. Improving rates of thrombolysis
delivery, even after medical treatment has been sought,
involves challenges at several levels, including paramedic
recognition of stroke prior to hospital arrival, attendance
at a tPA-capable hospital, prompt triaging from the
Emergency Department to a Stroke Care Team, rapid ac-
cess to CT or MRI scan to establish ischaemic stroke,
and the availability of appropriately-trained clinicians to
provide tPA. A description of the series of tasks involved
in the delivery of timely thrombolysis (see Table 1) illus-
trates the number of tasks, complexity, multidisciplinary
nature, and time urgency involved in successful delivery
of thrombolysis for acute stroke. An Australian study
at a single large teaching hospital (Pre-hospital Acute
Stroke Triage [PAST]) developed and implemented a
Table 1 Framework for situational analysis exploring phases of care, tasks, staff roles and time frames
Phase Task Staff Time frame
1. Pre-hospital
assessment
Assess potential tPA eligibility Paramedic <2 h of onset
Whether probable stroke or stroke mimic, define time of onset, consider comorbidity/frailty,
estimate for survival
Deliver to tPA-capable hospital Paramedic
Handover to triage or Acute Stroke Team to ED/SCU
2. Triage Assess tPA eligibility ED or SCU <3.5 h of
onset
Onset time, collateral history, mRS, anticoagulants, seizure, serious or advanced terminal illness,
history of intracranial haemorrhage or subarachnoid haemorrhage, major internal surgery in last
21 days, heart attack with IV thrombolysis in last 72 hours, stroke severity assessment with
National Institutes of Health Stroke Scale, Glasgow Coma Scale, observations
Handover to SCU to Acute
Stroke Team
3. Clinical
assessment
Assess tPA eligibility SCU Nurse
Onset time certainty, functional independence, comorbidity, current medication, relative and
absolute contraindications, NIHSS score, collect blood, notify CT scanning & organise transport,
organise ECG
Handover to Imaging to
Radiography
4. Imaging Non- contrast CT scan (or perfusion CT or MRI) Radiography
Handover to SCU to SCU Nurse
5. Final clinical
assessment
Confirm tPA eligibility SCU Medical
Review information from phase 1-3, focussed history to check for stroke mimic, onset certainty,
premorbid functional independence, medication, contraindications, NIHSS, rapid cardiac and vas-
cular screen, check blood sent to lab, review ECG, review NCCT on console with radiographer
and again for degree of ischaemic change & possibility of stroke mimic, discuss scenarios with
patient and family
6. Preparation &
delivery
tPA Preparation SCU Nurse <4.5 h of
onset
Check serum glucose level, anticoagulant medication, International Normalized Ratio, Blood
Pressure, NIHSS.
Treat serum glucose or Blood Pressure if necessary and reassess SCU Nurse
Administer thrombolysis, with amount based on estimated patient weight SCU Nurse
7. Monitor Monitor and manage neurological status (NIHSS at 0 h, 1 h, 24 hrs), blood pressure and serum
glucose level
SCU/ICUstaff 24 h from tPA
delivery
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cers and a pre-hospital notification system following as-
sessment of system barriers [40]. The PAST study
demonstrated an increase in tPA rates from 4.7% to
21.4% [40].
Achieving multi-site change in thrombolysis rates for
acute stroke poses an even more complex challenge, with
very few published trials. One study looked at the benefits
and challenges of establishing stroke units [41], and two
trials have explored thrombolysis in particular. The US
Get-With-The Guidelines stroke project – a national qual-
ity improvement program – demonstrated an increase in
adherence to guideline recommendations for stroke from a
baseline rate for intravenous thrombolytics of 42.09% to
72.84% in the fifth year of the project [42]. The PRomoting
ACute Thrombolysis in Ischemic StrokE (PRACTISE) clus-
ter randomised trial in The Netherlands used the Break-
through approach – a quality improvement methodologyusing Plan-Do-Study-Act (PDSA) cycles – to change
clinical practice [43]. The PRACTISE trial found that a
significantly higher proportion of intervention group is-
chemic stroke patients presenting within four hours of
stroke onset were thrombolysed (44.5%) compared to is-
chemic stroke patients in the control group (39.3%)
[43]. However, patients in the intervention group expe-
rienced higher post-care dependency [43]. The PRAC-
TISE trial authors suggested a need for a more intense
intervention with continuous process measures to achieve
more substantial improvements in thrombolysis rates [43].
Studies of the Breakthrough approach in other settings
have produced mixed results [44,45], which may suggest
the need for additional strategies or a more intensive
approach in order to achieve sustained change in com-
plex systems. The INSTINCT cluster randomised con-
trolled trial [46] of 24 acute-care community hospitals in
the US used a multilevel, barrier assessment-interactive
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cational elements, assessment of barriers, audit and
feedback. Trial results indicated a modest increase
in the proportion of admitted stoke patients receiving
thrombolysis between pre- and post-intervention periods
(1.25% and 2.79% at intervention hospitals, compared to
1.25% and 2.10% at control hospitals using Intention to
Treat analysis) but showed non-significant differences be-
tween groups. The authors concluded that additional
strategies are needed in order to increase acute stroke
treatment.
Therefore, a need remains for a rigorous trial of usual
approaches versus a comprehensive and intensive strat-
egy for increasing thrombolysis rates in a manner suit-
able for large scale implementation. The Thrombolysis
ImPlementation in Stroke (TIPS) study aims to provide
a robust test of a theory and evidence-driven multi-
component and multidisciplinary collaborative approach
designed to achieve sustained change in complex health
systems over multiple sites.
Aims
The study aims to test, using a cluster randomised con-
trolled trial, whether a multi-component multidisciplin-
ary collaborative approach can:
1. Increase the proportion of all stroke patients
receiving thrombolysis at intervention hospitals,
compared with control hospitals at follow-up
(Primary Outcome);
2. Maintain best-practice benchmarks of 30% of
patients achieving 3-month post-stroke modified
Rankin scores of 0 to 1 (little or no disability) at
both intervention and control sites (Secondary
Outcome);
3. Ensure that the adverse event rate for major
intracranial haemorrhage (parenchymal haematoma)
in thrombolysed patients does not rise above
best-practice benchmarks of 6% [19] in either
intervention or control hospitals (Secondary
Outcome).
Methods and design
The cluster randomised controlled trial will involve 20
hospitals in the Eastern Australian states of New South
Wales (NSW), Victoria (VIC) and Queensland (QLD).
Hospitals are the unit of randomisation and the unit of
analysis. SCUs manage the majority of stroke patients
across the Eastern states of Australia. Hospitals in
the intervention group will receive a multicomponent
multidisciplinary collaborative intervention based on
behavioural principles as described by the Behaviour
Change Wheel framework for the design and implemen-
tation of evidence-based practice [47]. The controlhospitals will receive no intervention and are free to
make practice changes of their own accord. Thus the
study is an implementation effectiveness trial rather than
an efficacy trial. The follow-up period will be two years
post-baseline (i.e., Year 1 to 2 = baseline, Year 3 = inter-
vention, Year 4 = follow-up), with an additional three
months for measurement of functional outcomes for
those thrombolysed in the final month of follow-up.
Figure 1 describes the study design.
Sample
Inclusion criteria
Eligible hospitals are those with a Stroke Care Unit or
staffing equivalent of a stroke physician and stroke
nurse; an Emergency Department and where the hospital
is at early stages of thrombolysis implementation. All
participating hospitals are required to record every con-
secutive case of stroke and thrombolysis, including ad-
verse events and patient functional outcomes at three
months. Both public and private hospitals are eligible to
be included in the sample, as are both teaching and
non-teaching hospitals.
Stratified randomisation Hospitals will be stratified ac-
cording to their stroke thrombolysis rates at baseline: very
low (0% to ≤4.00%), low (>4.00% to ≤10.00%) or moderate
(>10.00%). Baseline thrombolysis rate was considered
important for the following reasons: A ‘very low’ thromb-
olysis rate suggests some impediments to thrombolysis,
potentially limiting the ability of the site to respond
quickly to the intervention. Sites categorised as having a
‘low’ thrombolysis rate may have the greatest potential for
achieving change during the study, due to having substan-
tial room for improvement. Conversely, a site with a ‘mod-
erate’ baseline rate of thrombolysis may have limited
opportunity to demonstrate further substantial improve-
ment on the outcome measure.
Hospitals will be randomised at one time (effectively
achieving allocation concealment) to either the interven-
tion arm or the control arm with a 1:1 allocation ratio,
using a computer generated stratified randomisation
scheme in StatsDirect. Intervention hospital staff will
not be effectively blinded to their allocation, in that they
will be aware of their own involvement in intervention
activities. There will be minimal interaction with control
hospitals during the intervention phase.
Procedure
Site recruitment
Eligible hospitals were identified from National Stroke
Foundation (NSF) audit records and state-based clinical
SCU networks. Clinical leaders in stroke at each poten-
tially eligible hospital have been contacted by a clinical
leader from the research team to verify eligibility and
Identification and selection of eligible hospitals from NSF 
database and SCU clinical networks
Exclude hospitals with
- advanced thrombolysis delivery
-no SCU or equivalent
Hospital recruitment (n=20)
Clinical leads contact hospitals for recruitment
Baseline 2011-2012 (24month) thrombolysis rate per hospital as
per TIPS database hosted on the NSF website and ICD codes. Hard
copy self-complete staff perceptions survey distributed by sites
Stratify hospitals on baseline thrombolysis rate. Randomly 
allocate within a 3 tPA-rate strata (0-<4%, >4-<10%, >10%)
Intervention Group (n=10) Control Group(n=10)
Intervention Activities
- Preworkshop meeting
- Collaborative communal workshops
- Site workshops & bi-weekly meetings
- Web-based training modules
- Regular case monitoring
- Bi-monthly performance feedback
- Bi-monthly problem solving
teleconference
Follow-up (12 month) thrombolysis rate per hospital
Ye
ar
 1
-2
Ye
ar
 3
Ye
ar
 4
Figure 1 Study design & timeframe.
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in-principle support to participate in the study following
discussions with relevant decision makers at each site. A
signed memorandum of understanding or equivalent
consent agreement between each hospital and the re-
search team has documented agreement by all relevant
parties to collaborate for the whole period of the study.
Ethical approval for the study has been obtained from
relevant human research ethics committees in each state,
from each participating hospital and from The Univer-
sity of Newcastle Human Research Ethics Committee.
Data collection
Information on each patient thrombolysed during the
study period will be entered into the secure TIPS data-
base hosted on the National Stroke Foundation (NSF)website. Stroke imaging will be entered via an additional
INternational Stroke Perfusion Imaging REgistry (IN-
SPIRE) website designed for imaging data that will be
linked to the TIPS database. The TIPS database is only
accessible via secure logins and will be maintained by
the NSF. The patient data will be entered by the stroke
care nurse at each participating hospital as de-identified
patient unit record data. Data quality including range
checks will be undertaken. The research team will not
have access to identifying information about individual
clinicians, hospital staff, or data identifying individual
patients other than in the normal course of their existing
clinical duties. Electronic data files will be securely pro-
tected so that only the principal researchers will have ac-
cess to these data. Staff members from participating
departments at each hospital will be asked to complete
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ceived barriers and facilitators to thrombolysis imple-
mentation at their hospitals. This survey will be repeated
at follow-up.
Measures
Primary outcome
Numerator: The numerator is the number of cases treated
with thrombolytic therapy in each hospital. The following
details will be recorded for each thrombolysed case: age,
gender, date and time of stroke onset, date and time of
arrival at treating hospital, date and time of brain imaging
examination, time of tPA treatment, mRS grade before
stroke (premorbid mRS), stroke severity (NIHSS Scale),
hypertension, diabetes, hyperlipidaemia, smoking status
(current or previous), previous diagnosis of stroke, atrial
fibrillation (including paroxysmal), congestive heart fail-
ure, aspirin at stroke onset, dipyridamole at stroke onset,
clopidogrel at stroke onset, anticoagulants (oral) at stroke
onset, glucose level before treatment, and mRS at three
months post-treatment. Patient imaging data will be
uploaded via the INSPIRE database and will include: non-
contrast CT (NCCT), perfusion CT (CTP), CT angiog-
raphy (CTA), and Magnetic Resonance Imaging (MRI).
Denominator: The denominator is the number of cases
with a primary discharge diagnosis code of stroke (ICD-
10-AM I60.9, I61, I63, I64) that will be extracted from
hospital records. The accuracy of ICD coding for all
types of stroke is good [48-51], with a NSW tertiary hos-
pital reporting 96% accuracy in stroke discharge diagno-
sis identified by a random selection of stroke medical
records [50,51]. Another Australian study reported high
levels of reliability and adherence to coding standard for
ICD-10 codes [52], with a study of stroke attack rates
and case fatality in the Hunter Region reporting 97.5%
accuracy between stroke coding and audit [53]. Valid-
ation of Australian data sets for stroke diagnosis found
93% coding accuracy levels [49], and a Canadian study
reported 92% coding accuracy using ICD-10 codes for
stroke [54].
The primary outcome is the stroke thrombolysis rate
for each hospital, calculated as the number of stroke
cases thrombolysed divided by the total number of indi-
viduals with a stroke primary discharge diagnosis.
Secondary outcome
The secondary outcomes include intracranial haemor-
rhage as defined by the SITS registry and functional out-
comes at three months post stroke using the modified
Rankin Scale (mRS) [55]. Intracranial haemorrhage events
(parenchymal haematoma) will be identified from the
TIPS database and will be monitored annually during the
intervention and follow-up phases by the research team to
ensure that it does not exceed international benchmarks[56]. Sites will be provided with additional support if
benchmarks are exceeded. Monitoring of secondary out-
comes will not interfere with established governance pro-
cesses for reporting and monitoring of adverse events in
the health system. Functional outcomes will be scored as
good (mRS = 0 to 1) or poor (mRS = 2 to 6) by the treating
clinician or stroke nurse. The mRS has demonstrated reli-
ability and validity for use by clinicians and stroke nurses
[57]. The percentage of tPA-treated stroke cases having a
good outcome (mRS <2) at three months post stroke will
also be monitored annually by clinical experts in the re-
search team through the post-intervention NSF data
collection.Process measures
Pen and paper staff surveys will be conducted at all
participating hospitals regarding perceived barriers and
facilitators to tPA implementation. Survey items in-
clude: perceptions of tPA efficacy, local policies about
tPA, knowledge of tPA, skills relating to assessment for
and administration of tPA, challenges in tPA implemen-
tation, training relating to tPA, expertise and confidence
in relation to tPA, contingencies relating to tPA, partici-
pant’s gender, age, experience, staff role, and estimated
rates of tPA administration. For intervention hospitals,
engagement with each intervention activity will be
assessed, including number and type of staff from each
site attending each workshop or meeting. Assessment of
baseline overall readiness for change will also be assessed
by a member of the research team using a readiness for
change checklist based on the work of Warrick et al.
(2009), Kasurinen et al. (2002), and the National Institute
for Health and Clinical Excellence (2007). The full version
of the process measure tools can be obtained from the
corresponding author.Intervention components and activities
The TIPS intervention components described below are
grounded in behavioural theory and accord with the Be-
haviour Change Wheel (BCW) method [47]. The BCW
emphasises the importance of ensuring that proponents
have the capability, opportunity and motivation to per-
form the desired behaviour through interventions such
as education, persuasion, incentivisation, coercion, train-
ing, restriction, environmental restructuring, modelling
and enablement. A situational analysis based on the ‘pa-
tient journey’ is a foundational intervention component
in that it delineates the steps and associated staff roles
involved in successful delivery of thrombolysis. The TIPS
intervention components are delivered via a number of
intervention activities, the timing and content of which
is presented in Figure 2.
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patient journey
Careful delineation of the phases of care was carried
out by the research team on the basis of earlier work
at a single site [40], beginning at the point of seeking
emergency medical care (hospital or paramedic). The
situational analysis follows the journey of a stroke pa-
tient including pre-hospital assessment, triage, clinical
assessment, imaging, final clinical assessment, prepar-
ation and delivery of thrombolysis. The tasks and staff
roles involved along the patient journey are described
in Table 1. Examination of how well each of the steps
and roles described in the situational analysis will
be implemented at a particular site is embedded in
a number of intervention activities, including a pre-
workshop meeting between the primary change agent
and the champions at each site, collaborative work-
shops involving a team from each site, and site-based
working group meetings. In the context of each of
these intervention activities, the situational analysis fa-
cilitates identification of barriers and facilitators to in-
creasing the number of patients who are appropriately
thrombolysed.INTERVENTION ACTIVITY
&
Included Components
Pre-workshop meetings
Meeting of primary change agent and Site Champions for situation
analysis and preliminary target setting. Meeting of primary change 
and hospital executives or administrators
Collaborative communal workshops
Meeting of representatives from site working groups with research 
for situational analysis, performance feedback, motivation from prim
change agent, information-based target setting, inter-site collabora
problem solving,  professional development of champion skills
Site-based  working group workshops & fortnightly meetings
Site team meets with researchers for a mini workshop re situationa
analysis, motivation via change agents, information-based target s
intra-site collaborative problem solving. Ongoing site meetings re a
planning, performance monitoring,intra-site problem solving.
Web-based Training Modules
Web-based modules for all staff involved in stroke care for profess
development in clinical decision making re thrombolysis
Regular telephone case monitoring
Primary change agent contacts Site Champions to monitor perform
regarding decision and outcomes for thrombolysed cases
Bi-monthly feedback of tPA rate
Comparative performance feedback to members of each site worki
group
Bi-monthly inter-site teleconferences
Teleconference with primary change agent and site representative
inter-site collaborative problem solving
Figure 2 Timing of delivery of intervention activities.Component 2. Change agents - educating,
persuading and modelling
Much of the work on organisational change emphasises
the importance of champions or leaders in order to in-
crease the rate of adoption of a desired change [58,59].
In the context of TIPS, change agents will interact with
participants to educate, persuade and model desired be-
haviours throughout the change process. TIPS change
agents include primary change agents who liaise with
each of the intervention sites and change agents or
‘champions’ located at each site. Stroke nurses from the
research team will act as stroke nurse ‘champions’ to
monitor and encourage completion of the nurse profes-
sional development training (see Component 5). Mem-
bers of the research team (CL, MP, CB) have been
identified as the primary change agents, selected on the
basis of meeting criteria for leadership and ability to en-
act education, persuasion and modelling at a national
level [59]. The activities of the primary change agents in-
volve identification of Site Champions and assisting the
Site Champions with obtaining endorsement from senior
hospital administrators or executives. During the interven-
tion phase, the primary change agent will make regularMONTHS
1 2 3 4 5 6 7 8 9 10 11 12
al
agent
team
ary 
tive
l 
etting, 
ction
ional 
ance
ng
s for 
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or concerns relating to recent cases of thrombolysis.
The primary change agents will also lead education and
training aspects of the communal workshops, and at-
tend site workshops. The Site Champions will be the
drivers of change at each site, engage with those in-
volved in clinical work flow decisions, and will form a
working group comprising key local staff from para-
medicine, emergency, stroke care, and imaging. The Site
Champions will lead the site working groups in setting
goals, identifying actions, and reviewing performance
designed to achieve change. The Site Champions are se-
lected on the basis of clinical role (generally lead neur-
ologist and lead stroke nurse).Component 3. Information-based target setting –
persuasion and incentivisation
Target setting has been established as an important
motivator and driver of change on an individual and
system level [60]. Information-based target setting in-
volves a process of setting overall targets for appropri-
ate and achievable rates of thrombolysis for each site.
Importantly, a series of interim targets or successive
approximations will be set during the course of the
intervention period.
During the pre-workshop meeting, the Site Cham-
pions at each intervention hospital will set a preliminary
target for increased tPA administration at that hospital
with the guidance of the primary change agent. This tar-
get will be reviewed at the first communal workshop in
collaboration with members of the site-based working
group. Targets are framed based on baseline thromboly-
sis rates and should be challenging but achievable to
create a collective expectation of change and experience
of achievement. Interim targets will also be set, based
on perceived achievable changes in performance in suc-
cessive three-month periods throughout the interven-
tion phase.Component 4. Collaborative problem solving -
education, modelling and enablement
Collaborative problem solving is central to commonly-
used quality improvement strategies [61-63] and aims to
harness the knowledge, skills and support of a group.
Collaborative problem solving will occur within site
working groups during their bi-weekly meetings. Bi-
monthly teleconferences between the primary change
agent and representatives from each of the intervention
site-based working groups will explore experiences of all
groups in relation to identifying barriers and implement-
ing solutions. An evidence-based process will be used
whereby groups attempt to analyse the problem before
attempting to search for a viable solution [63].Component 5. Professional development –
education, training and restriction
Detailed education and training regarding clinical deci-
sion making for thrombolysis will be provided via web-
based educational modules with a strong emphasis on
achieving accepted levels of competency in key skills
such as decision making. Web-based approaches pro-
vide highly accessible, flexible and effective approaches
to learning, particularly when an interactive case-based
approach is used [64]. The TIPS website is available
to intervention sites via a unique log-in for each
participant.
For clinicians, the website contains didactic training
modules with a test at the end of each module and a
series of case studies where clinicians test their clinical
judgement against a consensus-based logic frame for a
set of stroke cases. In each case, the clinician is
provided with feedback regarding the appropriateness
of the decision and links to further reading if required.
Clinicians are asked to continue with the case studies
until they have achieved an agreed level of competence
in decision making. Lead clinicians are asked to ensure
that all relevant staff including emergency physicians
and registrars complete the training prior to caring for
potential stroke patients. The website provides
information and training for paramedics in the
identification of potential stroke patients. Both the
clinician and paramedic training modules were
developed by members of the TIPS research team and
colleagues.
NET SMART-Junior, a distance-accessible competency-
based learning system covering evidence-based manage-
ment of acute stroke patients, will serve as the educational
platform for standardised nursing education in the
TIPS trial. The NET SMART system offers rolling
entry/completion times supported by self-learning paced
programming. NET SMART-Junior is accredited by the
Arizona State University, College of Nursing and Health-
care Innovation (Tempe, Arizona, USA) to deliver con-
tinuing education credits internationally for completion
of modular units consisting of pre-test/post-test and clin-
ical skills measures. TIPS participants will be asked to
complete a selected number of training modules and to
discuss their results with their nurse ‘champion’.
The TIPS website also contains scientific literature re-
lating to thrombolysis, and tools and resources such as
those from the PAST trial [40]. In addition to training in
decision making skills, training in the skills of being a
champion will be provided. Change champion training
will also occur as a component of the communal work-
shops in the form of group-based reflective activities,
followed by self-directed tasks and opportunities for en-
gaging with ongoing external training or self-directed
learning.
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modelling
Given the strategic importance of providing perform-
ance feedback in order to achieve clinical practice
change [65,66], local and comparative feedback will be
provided. Sites will be provided with their three-
monthly estimated proportion of ischaemic stroke cases
who receive thrombolysis, graphed against site targets.
Comparative data will be provided, showing each site
how it compares to other intervention hospitals in a de-
identified format (i.e., other hospital names not dis-
closed), to create a positive level of competition among
peers. This information will be made available to the
participants via their unique logins on the TIPS website
and also forwarded directly to Site Champions.
Intervention sustainability
Achieving sustainability: Throughout the intervention
period, there will be a focus on identifying and enacting
strategies to embed changes in practice and ensure on-
going practice is monitored via mandatory recording
and reporting of thrombolysis delivery. During every col-
laborative intervention activity (e.g., workshops, site-
based meetings, inter-site teleconferences), sustainability
will be discussed in order that a strong focus on sustain-
ability is maintained. Strategies for achieving sustainabil-
ity will include: i) key steps in the process of care (e.g.,
time from arrival to handover to stroke team and cover-
age of imaging services) as part of local standard record-
ing and internal reporting; ii) establishing ongoing
communities of practice/clinical networks or including
thrombolysis as one of the priority initiatives of existing
clinical networks; iii) establishing networks for ongoing
mentoring, including formal mentoring relationships
that link groups of staff across hospitals; iv) including
numbers and proportions of thrombolysed patients in
standard reporting to hospital executives and local
health districts; v) incorporating the requirement for
completion of the TIPS web-based training modules as
part of orientation for medical staff in all relevant depart-
ments; and vi) establishment of the web-based training as
a locally-recognised professional credential required for
those involved in the care of stroke patients in the local
health district. Site-based working groups will also be en-
couraged to identify and enact other locally-relevant strat-
egies for achieving sustainability.
Measuring sustainability: Progress in achieving the
above sustainability strategies will be monitored during
both the intervention and follow-up phases via bi-
monthly site teleconferences and post-test staff surveys
as part of the study process measures. The degree to
which each of the intervention activities (regular site
working group meetings, completion of training modules
by new staff, entry and monitoring of the number ofthrombolysis cases) continues to occur during the
follow-up period (Year 4) will also be monitored as part
of the study process measures.Sample size
From baseline data, it is estimated that participating hos-
pitals will have an average of approximately 150 stroke
patients per year, that 5% of stroke patients in the con-
trol group will be prescribed tPA, and that the average
co-efficient of variation across strata will be approxi-
mately 0.4. With 10 hospitals per group, the study will
have 80% power with a 5% significance level to detect an
absolute difference of 7% to 10% [67]. The subgroup
analysis of hospitals with baseline tPA rate of <10% will
also have similar power to detect this difference, as, al-
though the number of hospitals per group will be
smaller, the baseline tPA rate will also be lower.Statistical methods
Primary outcome: Analysis will involve cluster-level sum-
mary data. The difference in post-intervention thromboly-
sis rates between intervention and control groups will be
compared via a two-stage approach to adjust for baseline
thrombolysis rates, using a stratified t-test.
Secondary outcomes: The proportion of thrombolysed
cases with good outcomes (mRS scores of 0 to 1) and
the proportion with intracranial haemorrhage at each
hospital will be compared to benchmarks (using a one
tailed hypothesis test) and analogous methods to stop-
ping rules for randomised clinical trials. Thresholds be-
yond which intervention is required will be calculated
using one-sided hypothesis tests adjusted for annual
checks. There will be intervention thresholds, beyond
which quality assurance processes would be instituted,
and stopping thresholds, beyond which tPA administra-
tion would be suspended until processes are reviewed.
Because we are conducting three analyses, we have used
the method of O’Brien-Fleming to determine signifi-
cance levels for each of the three analyses (this method
provides more stringent stopping criteria for early ana-
lysis). The appropriate significance levels are 0.0006,
0.0151 and 0.0471 for analysis 1, 2 and 3 respectively.
Analysis will be intention to treat in that all individuals
administered tPA should be included in the study data-
base, and the denominator will be obtained directly from
computerised hospital admissions data.
Secondary analyses: Given that there may be limited
potential for hospitals with high baseline tPA rates to
substantially further increase tPA administration, we
will undertake a subgroup analysis of the primary out-
come excluding hospitals with a baseline tPA of more
than 10%.
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The trial has been registered with the Australian New
Zealand Clinical Trials Registry: ACTRN12613000939796
and has obtained a UTN number: U1111-1145-6762.
Discussion
TIPS is one of the few studies to rigorously trial a com-
prehensive, multi-component and multidisciplinary col-
laborative approach to improving thrombolysis rates at
multiple sites, and builds substantially on the promising
work of the PRACTICE trial [43] and the INSTINCT
trial [46], which both emphasised the need for a more
intensive approach, such as that proposed for TIPS. The
study findings will occur in the context of a range of
challenges and limitations as described below. TIPS has
the potential to identify methods by which optimal care
can be effectively implemented on a large scale for
stroke patients during the acute phase. Trial outcomes
will be published whether significant or not.
Key study limitations and challenges
Measurement of primary outcome – tPA rates
The measurements of both the numerator and denomin-
ator for the primary outcome are challenging. The study
numerator is entered by the participating site, rather
than by an independent, blinded auditor, therefore intro-
ducing potential bias. The study denominator – medical
coding of all stroke cases – is independent and blinded
in that medical coders at each hospital are unaware of
the project. The denominator is also an approximation
in that it includes all stroke cases rather than only is-
chaemic stroke cases.
Group allocation not able to be blinded
A hospital’s random allocation to intervention or control
group cannot be concealed due to the nature of the inter-
vention. Therefore, additional potential bias is introduced.
Engagement of paramedic/ambulance service
The Ambulance Service has been approached to partici-
pate in this project. They will provide the ‘in-field’ con-
text for ischaemic stroke identification and management.
It is unlikely but possible that ambulance officers partici-
pating in the project will cover both control and inter-
vention hospitals and that any changes in their protocols
or procedures resulting from this project may have an
impact on both control and intervention sites. This can-
not be controlled for in the study design.
External factors
Other factors that may influence the results of the study,
but cannot be controlled for, include policies, guidelines,
or any health reforms being rolled out during the inter-
vention period. There may also be new informationregarding the tPA drug or other treatments of ischaemic
stroke becoming available during the lifespan of this
project, thus potentially affecting the results of the study.
However, any benefit from these initiatives reasonably
can be expected to impact equally on control sites as on
intervention sites. Any adverse events associated with
this study may also impact the outcomes of the study,
especially if they garner media attention. These external
factors will be monitored and included in the discussion
of study findings.
Notwithstanding these limitations, TIPS has significant
rigour given the large cluster RCT design, stratification on
baseline tPA rates, and objective outcome measurement.
Changes to this protocol
The TIPS Working Group will report any changes to this
Protocol to the TIPS Steering Committee and relevant Hu-
man Research Ethics Committees. Changes will also be re-
ported in published papers emerging from this trial.
Conclusions
TIPS has the potential to make a major contribution to the
implementation of translational literature, given the com-
bination of a theoretically driven, comprehensive interven-
tion strategy and rigorous outcome measurement.
Abbreviations
TIPS: Thrombolysis ImPlementation in Stroke; tPA: Tissue plasminogen
activator (also referred to as PLAT); NSF: National Stroke Foundation
(Australia); INSPIRE: INternational Stroke Perfusion Imaging REgistry; SITS: Safe
Implementation of Thrombolysis in Stroke registry (Australia); SCU: Stroke
care unit; NIHSS: National Institutes of Health Stroke Scale; NHMRC: National
Health and Medical Research Council; mRS: Modified rankin score;
MORUCOS: The Model Of Resource Utilization, Costs, and Outcomes for
Stroke; PAST: Pre-hospital Acute Stroke Triage; CT: Computed Tomography;
NCCT: Non-contrast Computed Tomography; CTP: Perfusion Computed
Tomography; CTA: Computed Tomography Angiography; MRI: Magnetic
resonance imaging; IV: intravenous; ED: Emergency Department;
ECG: electrocardiogram.
Competing interests
The authors declare that they have no competing interests. Boehringer
Ingelheim is a collaborative partner in this project and will have a clear
interest in increasing the use of the tPA drug. They have, however, no rights
to publish any results arising from this project.
Authors’ contributions
The following authors contributed considerably to study design and critically
revised the article: CA, JRA, CFB, HB, GC, CAD, SD, HD, ME, GD, RG, SG, AG,
RG, JG, GH, FH, KH, SH, AJ, EK, EL, AL, CRL, RIL, ML, SM, KM, BP, MWP, CLP,
MP, CP, SR, AR, RSF, AS, RS. All authors read and approved the final article. In
addition to this, CLP drafted the article and assisted with site recruitment,
CRL provided clinical expertise and managed site recruitment, CAD and JRA
provided statistical expertise, FH provided IT and website expertise, AR
co-drafted the article and managed ethics applications and agreements with
sites, EK assisted with the acquisition of data, RSF provided health behaviour
expertise, MWP, CFB, RIL, EK, ML and SM provided expertise in the
development of the TIPS training modules, AG managed ethics applications
and agreements with sites, KM assisted with site recruitment and the
development of training resources, SR and RS assisted with the development
of TIPS training modules, and AS provided health economic expertise. The
following authors contributed considerably to the acquisition of data and
critically revised the article: IB, CB, EB, ZC, TC, AC, SD, JD, MD, FG, RG, KH, JH,
Paul et al. Implementation Science 2014, 9:38 Page 11 of 13
http://www.implementationscience.com/content/9/1/38BJ, MJ, MK, MK, MK, SK, PL, SL, KL, BM, EM, KM, KM, SM, EOB, KP, RP, FR, JR,
MS, ST, ZT, NT, JW, AW, YW, TW, NW. All authors read and approved the final
article. The following authors were part of the writing group for the article:
CLP, CRL, CAD, MWP, CFB, RIL, JRA, FH, EL, ML, SM, AR, EK, RSF.
The Thrombolysis ImPlementation in Stroke (TIPS) Study Group:
Mr Craig Anderson4,6
Dr Ian Bruce7
Dr Heather Buchan8
Ms Camelia Burdusel9
Associate Professor Ernest Butler10
Mr Greg Cadigan11
Ms Zoe Campbell12
Mr Tim Coles13
Professor Alistair Corbett14
Ms Susan Day15
Ms Sonia Denisenko16
Ms Jenny Dennett13
Associate Professor Helen Dewey17,18
Professor Geoffrey Donnan17,19
Ms Michelle Doughty20
Mr Malcolm Evans3
Dr Frances Gearon21
Dr Richard Geraghty22
Professor Richard Gerraty12
Dr Sumitha Gounden21
Ms Alice Grady1,2
Dr Rohan Grimley23
Dr Jeremy Grimshaw24
Professor Graeme J Hankey25,26
Dr Kelvin Hill5
Ms Kim Hoffman27
Ms Sue Huckson28
Dr James Hughes29
Ms Amanda Jayakody1,2
Dr Bronwyn Jenkins30
Dr Martin Jude31
Mr Malcolm Kanard30
Dr Matthew Kinchington32
Associate Professor Martin Krause15
Ms Sarah Kuhle22
Dr Paul Laird33
Dr Andrew Lee34,35
Dr Stanley Levy36
Ms Karen Longworth7
Ms Beverley Macdonald36
Ms Elizabeth Mackey37
Dr Krishna Mandaleson13
Ms Katherine Mohr31
Dr Stephen Moore27
Ms Kristy Morris3
Ms Elizabeth O'Brien15
Mr Bruce Paddock38
Ms Kim Parrey32
Ms Rachel Peake29
Associate Professor Michael Pollack1,3
Mr Christopher Price19
Ms Shiho Rose1,2
Dr Jayantha Rupasinghe10
Ms Fiona Ryan21
Dr Andrew Searles1
Ms Rochelle Smits1,2
Ms Margaret Stevenson10
Dr Sanjeev Taneja20
Dr Zoe Terpening39
Ms Natalie Teasdale37
Professor John Watson39
Ms Alison Wilson14
Dr Yolande Weiner40
Associate Professor Tissa Wijeratne17,37
Dr Nigel Wolfe9Affiliations
1The University of Newcastle (UoN), University Drive, Callaghan NSW 2308
2Hunter Medical Research Institute (HMRI) 1/Kookaburra Circuit, New
Lambton Heights NSW 2305
3Hunter New England Health, Lookout Road, New Lambton NSW 2305
4The University of Sydney, City Road Darlington NSW 2008
5National Stroke Foundation, Level 7, 461 Bourke Street, Melbourne VIC 3000
6The George Institute for Global Health, level 13, 321 Kent Street, Sydney
NSW 2000
7Coffs Harbour Health Campus, 345 Pacific Highway, Coffs Harbour, NSW
2450
8Australian Commission on Safety and Quality in Health Care (ACSQHC), level
5, 255 Elizabeth Street, Sydney NSW 2000
9Blacktown Mount Druitt Hospital, 18 Blacktown Road, Blacktown NSW 2148
10Frankston Hospital, 2 Hastings Rd, Frankston VIC 3199
11Queensland Health Statewide Stroke Clinical Network (SSCN), C/-Clinical
Access & Redesign Unit, GPO Box 48, Brisbane QLD 4001
12Epworth HealthCare, 89 Bridge Road, Richmond VIC 3121
13Central Gippsland Health Service, 155 Guthridge Parade, Sale VIC 3850
14Concord Repatriation General Hospital, Hospital Road, Concord NSW 2139
15Royal North Shore Hospital, Northern Clinical School, University of Sydney,
Kolling Building Level 7, Royal North Shore Hospital, Reserve Road, St
Leonards, NSW 2065
16Victorian Stroke Clinical Network, 50 Lonsdale Street, Melbourne VIC 3000
Australia
17The University of Melbourne, 1-100 Grattan Street, Parkville VIC 3010
18Austin Health, 145 Studley Rd, Heidelberg VIC 3084
19The Florey Institute of Neuroscience and Mental health, 30 Royal Parade,
Parkville VIC 3052
20Wollongong Hospital, 1 Crown Street, Wollongong NSW 2500
21Orange Base Hospital, Dalton Street, Orange NSW 2800
22Redcliffe Hospital, Anzac Avenue, Redcliffe QLD 2040
23The University of Queensland, Brisbane, St Lucia QLD 4072
24Institute of Population Health, University of Ottawa, 550 Cumberland St,
Ottawa, ON K1N 6N5, Canada
25School of Medicine and Pharmacology, The University of Western Australia,
Nedlands, WA 6009
26Department of Neurology, Sir Charles Gairdner Hospital, Hospital Avenue,
Perth, WA 6009
27Lismore Base Hospital, 60 Uralba Street, Lismore NSW 2480
28National Health and Medical Research Council (NHMRC), level 1, 16 Marcus
Clarke Street, Canberra, ACT 2601
29Tamworth Hospital, 31 Dean Street, Tamworth NSW 2340
30Hornsby-Ku-ring-gai Hospital, Palmerston Rd, Hornsby NSW 2077
31Wagga Wagga Base Hospital, Docker Street, Wagga Wagga NSW 2650
32Port Macquarie Base Hospital, Wrights Road, Port Macquarie NSW 2444
33Rockhampton Hospital, Canning Street, Rockhampton QLD 4700
34Flinders Medical Centre, Flinders Dr, Bedford Park, SA 5042
35Flinders University, Sturt Road, Bedford Park, SA 5042
36Campbelltown Hospital, Therry Road, Campbelltown NSW 2560
37Western Hospital, Gordon Street, Footscray, VIC 3011
38Ambulance Service of NSW, Balmain Road, Rozelle NSW 2039
39Sydney Adventist Hospital, 185 Fox Valley Road, Wahroonga NSW 2076
40Logan Hospital, Corner of Loganlea Road & Armstrong Road,
Meadowbrook QLD 4131
Acknowledgements
This project is funded by the National Health and Medical Research Council
(NHMRC) as a partnership grant (ID569328) and is part-funded by a TRIP
fellowship, with collaborative funding from Boehringer Ingelheim and in-kind
support from ACI Stroke Care Network/Stroke Services NSW, Victorian Stroke
Clinical Network, National Stroke Foundation (NSF) and NSW Cardiovascular
Research Network-National Heart Foundation, with infrastructure funding
from Hunter Medical Research Institute (HMRI) and The University of
Newcastle (UoN). The UoN is the coordinating centre, the TRIP fellowship
funds the research activities for the Clinical Champion, Boehringer Ingelheim
funds workshops, logistics and educational material, ACI Stroke Clinical
Network/Stroke Services NSW and Victorian Stroke Clinical Network provide
support for a stroke care coordinator’s time collating and entering tPA audit
results, and NSW Cardiovascular Research Network-National Heart
Foundation provides support for the involvement of a clinical practice
Paul et al. Implementation Science 2014, 9:38 Page 12 of 13
http://www.implementationscience.com/content/9/1/38change expert to support quality improvement strategies at each site. The
NHMRC partnership grant is covering the cost of the remaining project
activities. Although the Industry Partner is a manufacturer of the tPA drug
and therefore has a vested interest in increasing tPA rates, their involvement
is subject to strict guidelines, including non-involvement in the study design,
data collection, analysis and publications. The assistance of Kate Day and
Kate Ross in progressing toward launching the study is gratefully
acknowledged.
Roles and responsibilities
The TIPS Steering Committee is comprised of Chief Investigators and
external advisors. They are responsible for overseeing the design and
milestones of the project. The TIPS Working Group is a smaller group of
Chief Investigators and people driving the project, including Research
Assistants. They are responsible for data monitoring and report to the TIPS
Steering Committee. Boehringer Ingelheim has no representation on either
of these committees to ensure that study findings are independent of the
sponsor and their competing interest.
Author details
1The University of Newcastle, (UoN) University Drive, Callaghan, NSW 2308,
Australia. 2Hunter Medical Research Institute (HMRI) 1/Kookaburra Circuit,
New Lambton Heights, NSW 2305, Australia. 3Hunter New England Health,
Lookout Road, New Lambton Heights, NSW 2305, Australia. 4National Centre
for Epidemiology and Population Health, The Australian National University,
Barry Drive, Acton, ACT 0200, Australia. 5Box Hill Hospital, 16 Arnold Street,
Box Hill, VIC 3128, Australia. 6Westmead Hospital, Hawkesbury Road,
Westmead, NSW 2145, Australia. 7The University of Sydney, City Road,
Darlington, NSW 2008, Australia. 8National Stroke Foundation, Level 7, 461
Bourke Street, Melbourne, VIC 3000, Australia. 9Stroke Services NSW/ACI
Stroke Care Network, Level 4, Sage Building, 67 Albert Avenue, Chatswood,
NSW 2067, Australia. 10Australian Catholic University, 40 Edward Street, North
Sydney, NSW 2060, Australia.
Received: 3 December 2013 Accepted: 24 February 2014
Published: 25 March 2014
References
1. Mackay J, Mensah G: The Atlas of Heart Disease and Stroke. Geneva: WHO;
2004.
2. Compressed Mortality File 1999-2009: CDC WONDER Online Database,
compiled for Compressed Mortality File 1999–2009 Series 20, No. 20,
Underlying cause-of-death 1999–2009. 2012. Accessed August 20, 2012
[http://wonder.cdc.gov/mortSQl.html]
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata
DM, Dai S, Ford ES, Fox CS: Heart disease and stroke statistics—2013
update a report from the American heart association. Circulation 2013,
127(1):e6–e245.
4. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD,
Finkelstein EA, Hong Y, Johnston SC, Khera A: Forecasting the future of
cardiovascular disease in the United States a policy statement from the
American heart association. Circulation 2011, 123(8):933–944.
5. Household component summary data table. 2012. http://meps.ahrq.gov/
mepsweb/.
6. Australian Bureau of Statistics: Cardiovascular Disease in Australia: a snapshot,
2004-05. Canberra: ABS; 2006.
7. Australian Institute of Health and Welfare: Australia's health 2006. In The Economic
Impact of Stroke in Australia. Canberra: AIHW; 2006. Melbourne: NSF; 2013.
8. Deloitte Access Economics: The economic impact of stroke in Australia.
Melbourne: NSF; 2013.
9. Australian Institute of Health and Welfare: Stroke and its management in
Australia: an update. In Cardiovascular Disease Series. Canberra: AIHW; 2013.
10. National Stroke Foudation: National Stroke Audit – Acute Services Clinical
Audit Report 2011. Melbourne: NSF; 2011.
11. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS: Long-term
disability after first-ever stroke and related prognostic factors in the
Perth community stroke study, 1989–1990. Stroke 2002, 33(4):1034–1040.
12. International Stroke Trial Collaborative Group: The International Stroke Trial
(IST): a randomised trial of aspirin, subcutaneous heparin, both, or
neither among 19,435 patients with acute ischaemic stroke. Lancet 1997,
349(9065):1569–1581.13. Gilligan A, Thrift A, Sturm J, Dewey H, Macdonell R, Donnan G: Stroke units,
tissue plasminogen activator, aspirin and neuroprotection: which stroke
intervention could provide the greatest community benefit? Cerebrovasc
Dis 2005, 20(4):239–244.
14. Saver J, Fonarow G, Smith E, Reeves M, Grau-Sepulveda M, Pan W, Olson D,
Hernandez A, Peterson E, Schwamm L: Time to treatment with intravenous
tissue plasminogen activator and outcome from acute ischemic stroke.
JAMA 2013, 309(23):2480–2488.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue
V, Lees KR, Medeghri Z, Machnig T: Thrombolysis with alteplase 3 to
4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359(13):1317–
1329.
16. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL,
Cohen G: Recombinant tissue plasminogen activator for acute ischaemic
stroke: an updated systematic review and meta-analysis. Lancet 2012,
379(9834):2364–2372.
17. IST-3 Collaborative Group: Effect of thrombolysis with alteplase within 6 h
of acute ischaemic stroke on long-term outcomes (the third
International Stroke Trial [IST-3]): 18- month follow-up of a randomised
controlled trial. Lancet Neurol 2013, 12(8):768–776.
18. Hacke W, Donnan G, Fieschi C, Kaste M, Von Kummer R, Broderick J, Brott T,
Frankel M, Grotta J, Haley E Jr: Association of outcome with early stroke
treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke
trials. Lancet 2004, 363(9411):768–774.
19. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine R, Toni
D, Lees K, Investigators S: Thrombolysis with alteplase 3-4.5 h after acute
ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008,
372(9646):1303–1309.
20. Saver J, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P,
Starkman S: Number needed to treat to benefit and to harm for
intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour
window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009,
40(7):2433–2437.
21. del Zoppo G, Saver J, Jauch E, Adams H, American Heart Association Stroke
Council: Expansion of the time window for treatment of acute ischemic
stroke with intravenous tissue plasminogen activator: a science advisory
from the American heart Association/American Stroke Association. Stroke
2009, 40(8):2945–2948.
22. Buchan A, Barber P, Newcommon N, Karbalai H, Demchuk A, Hoyte K, Klein
G, Feasby T: Effectiveness of t-PA in acute ischemic stroke: outcome
relates to appropriateness. Neurology 2000, 54(3):679–684.
23. Saver J: Number needed to treat estimates incorporating effects over the
entire range of clinical outcomes: novel derivation method and application
to thrombolytic therapy for acute stroke. Arch Neurol 2004, 61(7):1066–1070.
24. Wardlaw J, Warlow C, Counsell C: Systematic review of evidence on
thrombolytic therapy for acute ischaemic stroke. Lancet 1997,
350(9078):607–614.
25. Hoffman JR, Cooper RJ: How is more negative evidence being used to
support claims of benefit: the curious case of the third international
stroke trial (IST-3). Emerg Med Australas 2012, 24(5):473–476.
26. Canadian Stroke Best Practices and Standards Working Group Canadian Best
Practice Recommendations for Stroke Care: Canadian best practice
recommendations for stroke care. Fourthth edition. Edited by Lindsay M,
Gubitz G, Bayley M, Phillips S. Ottawa: Canadian Stroke Network; 2013.
27. Party ISW: National Clinical Guideline for Stroke. 4th edition. London: Royal
College of Physicians; 2012.
28. National Stroke Foundation: Clinical guidelines for stroke management.
Melbourne: NSF; 2010.
29. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P,
McMullan PW, Qureshi AI, Rosenfield K, Scott PA: Guidelines for the early
management of patients with acute ischemic stroke a guideline for
healthcare professionals from the American heart association/American
stroke association. Stroke 2013, 44(3):870–947.
30. Samsa G, Reutter R, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J,
Matchar D: Performing cost-effectiveness analysis by integrating randomized
trial data with a comprehensive decision model: application to treatment of
acute ischemic stroke. J Clin Epidemiol 1999, 52(3):259–271.
31. Fagan S, Morgenstern L, Petitta A, Ward R, Tilley B, Marler J, Levine S,
Broderick J, Kwiatkowski T, Frankel M, Brott T, Walker M: Cost-effectiveness
of tissue plasminogen activator for acute ischemic stroke. Neurology
1998, 50(4):883–890.
Paul et al. Implementation Science 2014, 9:38 Page 13 of 13
http://www.implementationscience.com/content/9/1/3832. Moodie M: Trial application of a Model of Resource Utilization, Costs, and
Outcomes for Stroke (MORUCOS) to assist priority setting in stroke.
Stroke 2004, 35(5):1041–1046.
33. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R,
Neilson A, Wardlaw J: Cost-effectiveness of thrombolysis with recombinant
tissue plasminogen activator for acute ischemic stroke assessed by a model
based on UK NHS costs. Stroke 2004, 35(6):1490–1497.
34. Nguyen-Huynh MN, Johnston SC: Is hospitalization after TIA cost-effective
on the basis of treatment with tPA? Neurology 2005, 65(11):1799–1801.
35. National Health Priority Action Council (NHPAC): National service
improvement framework for heart, stroke and vascular disease. Canberra:
Australian Govenement Department of Health and Ageing; 2006.
36. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM,
Kwiatkowski T, Lyden PD, Marler JR, Torner J: Guidelines for thrombolytic
therapy for acute stroke: a supplement to the guidelines for the
management of patients with acute ischemic stroke a statement for
healthcare professionals from a special writing group of the stroke
council, American heart association. Circulation 1996, 94(5):1167–1174.
37. Fang M, Cutler D, Rosen A: Trends in thrombolytic use for ischemic stroke
in the United States. J Hosp Med 2010, 5(7):406–409.
38. Rudd A, Hoffman A, Grant R, Campbell J, Lowe D, Intercollegiate Working
Party for Stroke: Stroke thrombolysis in England, Wales and Northern
Ireland: how much do we do and how much do we need? J Neurol
Neurosurg Psychiatry 2011, 82(1):14–19.
39. Improving patient care: the implementation of change in clinical practice.
Edited by Grol R, Wensing M, Eccles M, Davis D. London: Elsevier:
Butterworth-Heinemann; 2005.
40. Quain DA, Parsons MW, Loudfoot AR, Spratt NJ, Evans MK, Russell ML, Royan
AT, Moore AG, Miteff F, Hullick C: Improving access to acute stroke
therapies: a controlled trial of organised pre-hospital and emergency
care. Med J Aust 2008, 189(8):429–433.
41. Cadilhac D, Ibrahim J, Pearce D, Ogden K, McNeill J, Davis S, Donnan G,
SCOPES Study Group: Multicenter comparison of processes of care
between stroke units and conventional care wards in Australia. Stroke
2004, 35(5):1035–1040.
42. Schwamm L, Fonarow G, Reeves M, Pan W, Frankel M, Smith E, Ellrodt G,
Cannon C, Liang L, Peterson E, LaBresh K: Get with the guidelines – stroke
is associated with sustained improvement in care for patients
hospitalized with acute stroke or transient ischemic attack circulation.
Circulation 2009, 119:107–115.
43. Dirks M, Niessen L, van Wijngaarden J, Koudstaal P, Franke C, van
Oostenbrugge R, Huijsman R, Lingsma H, Minkman M, Dippel D, PRomoting
ACute Thrombolysis in Ischemic StrokE (PRACTISE) Investigators: Promoting
thrombolysis in acute ischemic stroke. Stroke 2011, 42(5):1325–1330.
44. Schouten LM, Hulscher ME, Everdingen JJ, Huijsman R, Grol RP: Evidence
for the impact of quality improvement collaboratives: systematic review.
BMJ 2008, 336(7659):1491–1494.
45. Jones K, Piterman L: The effectiveness of the breakthrough series
methodology. Aust J Prim Health 2008, 14(1):59–65.
46. Scott PA, Meurer WJ, Frederiksen SM, Kalbfleisch JD, Xu Z, Haan MN,
Silbergleit R, Morgenstern LB: A multilevel intervention to increase
community hospital use of alteplase for acute stroke (INSTINCT): a
cluster-randomised controlled trial. Lancet Neurol 2013, 12(2):139–148.
47. Michie S, van Stralen MM, West R: The behaviour change wheel: a new
method for characterising and designing behaviour change
interventions. Implement Sci 2011, 6(1):42.
48. Ghia D, Thomas P, Cordato D, Worthington J, Cappelen-Smith C, Griffith N,
Hanna I, Hodgkinson S, McDougall A, Beran R: Validation of emergency and
final diagnosis coding in transient ischemic attack: South Western Sydney
transient ischemic attack study. Neuroepidemiology 2010, 25(1):53–58.
49. Gattellari M, Worthington J, Jalaludin B, Mohsin M: Stroke unit care in a
real-life setting Can results from randomized controlled trials be
translated into every-day clinical practice? An observational study of
hospital data in a large Australian population. Stroke 2009, 40(1):10–17.
50. Wang Y, Levi C, Attia J, D'Este C, Spratt N, Fisher J: Seasonal variation in
stroke in the Hunter region, Australia: a 5-year hospital-based study,
1995-2000. Stroke 2003, 34(5):1144–1150.
51. Wang Y, Levi C, D’Este C, Attia J, Fisher J: Variation of stroke attack rates in
rural, urban, and coalfields areas of the Hunter region, Australia,
1995-2000. J Stroke Cerebrovasc Dis 2003, 12(2):103–110.52. Henderson T, Shepheard J, Sundararajan V: Quality of diagnosis and
procedure coding in ICD-10 administrative data. Med Care 2006,
44(11):1011–1019.
53. Marsden D, Spratt N, Walker R, Barker D, Attia J, Pollack M, Parsons M, Levi
C: Trends in stroke attack rates and case fatality in the Hunter region
Australia 1996–2008. Cerebrovasc Dis 2010, 30(5):500–507.
54. Kokotailo R, Hill M: Coding of stroke and stroke risk factors using international
classification of diseases, revisions 9 and 10. Stroke 2005, 36(8):1776–1781.
55. Rankin L: Cerebral vascular accidents in patients over the age of 60. II.
Prognosis. Scott Med J 1957, 2(5):200–215.
56. Wahlgren N, Ahmed N, Dávalos A, Ford G, Grond M, Hacke W, Hennerici M,
Kaste M, Kuelkens S, Larrue V, Lees K, Roine R, Soinne L, Toni D, Vanhooren G,
SITS-MOST Investigators: Thrombolysis with alteplase for acute ischaemic
stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring
Study (SITS-MOST): an observational study. Lancet 2007, 369(9558):275–282.
57. Banks J, Marotta C: Outcomes validity and reliability of the modified
Rankin scale implications for stroke clinical trials: a literature review and
synthesis. Stroke 2007, 38(3):1091–1096.
58. Valente T, Davis R: Accelerating the diffusion of innovations using
opinion leaders. ANNALS Am Acad Polit Soc Sci 1999, 566:55–67.
59. Katz E: The two-step flow of communication: an up-to-date report on a
hypothesis. Publ Opin Q 1957, 21:61–78.
60. Strecher V, Seijts G, Kok G, Latham G, Glasgow R, DeVellis B, Meertens R,
Bulger D: Goal setting as a strategy for behaviour change. Health Educ
Behav 1995, 22(3):190.
61. Kilo C: A framework for collaborative improvement: lessons from the
institute for healthcare improvement's breakthrough series. Qual Manag
Health Care 1998, 6(4):1–13.
62. Plsek P: Collaborating across organizational boundaries to improve the
quality of care. Am J Infect Control 1997, 25(2):85–95.
63. Hirokawa R: Group communication and problem-solving effectiveness: an
investigation of group phases. Hum Commun Res 1983, 9(4):291–305.
64. Casebeer L, Engler S, Bennett N, Irvine M, Sulkes D, DesLauriers M, Zhang S:
A controlled trial of the effectiveness of internet continuing medical
education. BMC Med 2008, 6:37.
65. Grimshaw J, Thomas R, MacLennan G, Fraser C, Ramsay C, Vale L, Whitty P,
Eccles M, Matowe L, Shirran L: Effectiveness and efficiency of guideline
dissemination and implementation strategies; 2004.
66. Kawamoto K, Houlihan C, Balas E, Lobach D: Improving clinical practice
using clinical decision support systems: a systematic review of trials to
identify features critical to success. BMJ 2005, 330(7494):765.
67. Hayes R, Moulton L: Cluster Randomised Trials. London: Chapman and Hall;
2009.
doi:10.1186/1748-5908-9-38
Cite this article as: Paul et al.: Thrombolysis ImPlementation in Stroke
(TIPS): evaluating the effectiveness of a strategy to increase the
adoption of best evidence practice – protocol for a cluster randomised
controlled trial in acute stroke care. Implementation Science 2014 9:38.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
